|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A novel compound, ferulic acid-bound resveratrol, induces the tumor suppressor gene p15 and inhibits the three-dimensional proliferation of colorectal cancer cells.
|
31440879 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, its expression may be variable. p15 is a tumor suppressor encoded by CDKN2B, loss of which has been recently shown to promote transition from nevus to melanoma.
|
30666677 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Promoter methylation of p14 <sup>ARF</sup> , p15 <sup>IK4b</sup> and p16 <sup>INK4a</sup> was not detected in any tumor sample.
|
27377733 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, by binding to enhancer of zeste homolog 2 (EZH2), LINC00152 promotes GC tumor cell cycle progression by silencing the expression of p15 and p21.
|
26799422 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further mechanism study showed that, by binding to histone demethylase lysine-specific demethylase 1 (LSD1), an enhancer of zeste homolog 2 (EZH2), IRAIN reduced PC tumor cell apoptosis and induced growth arrest by silencing the expression of Kruppel-like factor 2 (KLF2) and P15.
|
27644252 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Western blotting showed that crotoxin increased p15 and caspase-3 p17 protein levels and reduced Bcl-2 protein level in tumor specimens.
|
23202800 |
2013 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Our results suggest that promoter methylation of p16 and MGMT genes could have prognostic value when used in combination with the FLIPI and p15 methylation in combination with tumor grade.
|
23275143 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicate that p15RS has malignancy inhibitory functions independent of cell cycle inhibition and provide novel insights on the role of p15 in tumor inhibition.
|
22580456 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Zebularine alone or in sequential combination with RA decreased expression of DNMT1, caused fast and time-dependent expression of pan-cadherin and partial demethylation of E-cadherin but not tumor suppressor p15.
|
21842375 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The additional loss of p15/Ink4b in tumors derived from cells that are already deficient in p16/Ink4a bolsters the hypothesis that p15 plays an important role in tumor suppression, especially in the absence of p16.
|
20663777 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, both p15 and p16 are frequently codeleted or transcriptionally co-inhibited with p14, essentially in tumors with two wild-type TP53 alleles.
|
20884963 |
2010 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The aim of our study was to test chromosomal aberrations detected by fluorescence in situ hybridization (FISH) in the diagnosis of MM in effusion cytology and to explore the potential role of p16, p14, and p15 gene methylation as an alternative mechanism of tumor suppressor gene inactivation.
|
20139227 |
2010 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, polymerase chain reaction (PCR) was used to assay several tumor suppressor genes of these cell lines, and homozygous deletions within chromosomal band 9p2l including MTAP (methylthioadenosine phosphorylase), p16 and p15 were detected.
|
20596646 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We observed promoter methylation of MGMT in 56% and of p15 in 37% of the tumors, whereas methylation of p16 and p14ARF were rare.
|
19424593 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have previously demonstrated that a proapoptotic cyclic peptide termed P15 delivered into the cells by the Tat Cell Penetrating Peptide was able to abrogate the CK2-mediated phosphorylation and induce tumor regression when injected directly into solid tumors in mice.
|
17847034 |
2008 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Inactivation of p15 by promoter hypermethylation has been postulated as a possible way by which tumor suppressor genes are inactivated in cancer.
|
17546638 |
2007 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Bisulfite sequencing of the p15 promoter in marrow DNA during the first cycle of treatment showed heterogeneous allelic demethylation in three responding patients, suggesting ongoing demethylation within the tumor clone, but no demethylation in two nonresponders.
|
16778214 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, frequently homozygous deletions occur in several kinds of cancer associated with the loss of tumour suppressor genes as p16 and p15.
|
16081515 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the promoters of the selected tumor suppressor genes p73 (48%), p16 (33%), CHFR (19%), p15 (10%), and TMS1 (10%) were hypermethylated in CTCL.
|
15897551 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In Ashkenazi patients, ERCC2 and MTHFR genes' SNPs were associated with age at diagnosis (ERCC2: p=0.025, MTHFR: p=0.0005); a P53 polymorphism, APOE and Rb SNPs with a family history of cancer (P53 p=0.034;APOE p=0.04, Rb p= 0.022); DCC SNP with tumor location (p=0.014); and p15 SNP with tumor grade (p=0.032).
|
15523694 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among 31 patients with HNSCC, 20 patients (65%) had methylated p15 gene in their tumor biopsies.
|
15221997 |
2004 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Interestingly, the methylation frequency of the CDH13 gene was comparable to those of the tumor suppressor genes p15 (68%) and p16 (74%) detected in B-DLCLs.
|
15289870 |
2004 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Concordant methylation of p16 and p15 in tumour samples and metastatic lymph nodes was found in 59 and 38% of cases, respectively.
|
12932666 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aberrant hypermethylation was observed in 7 (32%) and 5 (23%) cases accompanied, by immunohistochemical loss of expression for p16 and p15 genes respectively, in both high stage and grade tumors from patients living in radiocontaminated areas, this being especially outstanding for the p16 gene.
|
12218456 |
2002 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Our results show that although p16 and/or p15 methylation is involved in non-Hodgkin's and Hodgkin's tumors that share morphological and phenotypic features, differences in incidence, pattern of methylation, and implication in tumor progression are observed.
|
12213729 |
2002 |